GLP-1 Weight-Loss Drugs as a Possible Adjunct for Obstructive Sleep Apnea

Researchers at the University of Pittsburgh conducted a comprehensive literature review to assess whether glucagon-like peptide-1 (GLP-1) receptor agonists—such as Ozempic and Wegovy—might improve outcomes for patients with obstructive sleep apnea (OSA). The review, published in *JAMA Otolaryngology—Head and Neck Surgery* on September 3, concluded that existing evidence suggests GLP-1 drugs could have positive impacts for some OSA patients, particularly those whose condition is driven by excess body weight.

Newsweek

OSA affects nearly 1 billion people worldwide. Between 60 % and 70 % of those diagnosed are classified as obese (body-mass index >= 30), making obesity the primary modifiable risk factor. Excess neck fat narrows the airway, while abdominal and chest fat compress the lungs, reducing lung volume and increasing airway collapsibility. These physiological changes contribute to the repeated breathing interruptions that define OSA.

Newsweek

• The review searched PubMed, Cochrane Library, ClinicalTrials.gov and Google Scholar from January 2016 through November 2025, covering the period after the first randomized GLP-1 trial for OSA (the SCALE Sleep Apnea trial).

Newsweek

• The Wisconsin Sleep Cohort Study reported that a 10 % gain in body weight was associated with a 32 % rise in the apnea-hypopnea index, the metric used to gauge OSA severity.

Newsweek

• Across the studies examined, weight reduction consistently correlated with improvements in the apnea-hypopnea index.

Newsweek

Dr. Richard Schwab, a professor of medicine at the University of Pennsylvania (not involved in the review), described GLP-1 agonists as potential “game changers” for OSA treatment, emphasizing that they must be used alongside established therapies such as continuous positive airway pressure (Continuous Positive Airway Pressure (CPAP)) and that benefits may require four months to a year of sustained weight loss.

Newsweek

Dr. Alex Harris, lead author of the review, noted that GLP-1 drugs could diminish fatty deposits in the tongue and pharyngeal tissues, thereby reducing airway collapsibility, improving lung volume, and possibly stabilizing ventilatory control via central GLP-1 receptors. She cautioned that GLP-1 therapy is not a substitute for CPAP and that long-term medication adherence is essential for chronic disease management.

Newsweek

• “The pharynx, between the hard palate and larynx, is the only segment of the airway without rigid support,” — Dr. Alex Harris, lead author of the study

Newsweek

*The pharynx, between the hard palate and larynx, is the only segment of the airway without rigid support,* — Dr. Alex Harris, lead author of the study

Newsweek